Adverse Drug Reactions: A Review

被引：0
作者：
Munir N. Gharaibeh
Howard E. Greenberg
Scott A. Waldman
机构：
[1] Thomas Jefferson University,Division of Clinical Pharmacology, Departments of Medicine and Biochemistry and Molecular Pharmacology
[2] University of Jordan,Department of Pharmacology, Faculty of Medicine
来源：
Drug information journal : DIJ / Drug Information Association | 1998年 / 32卷 / 2期
关键词：
Adverse drug reaction; Drug effects; Epidemiology; Food and Drug Administration;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
The focus of this review is to increase the knowledge and raise the awareness of health care professionals with respect to adverse drug reactions (ADRs) and to integrate the various elements of this subject in a comprehensive fashion. The review addresses the definitions of ADRs, and their epidemiology, demographics, and economics. Risk factors for the development of ADRs are defined, their general pathophysiological mechanisms are presented (type 1 or “predictable “ and type 2 or “unpredictable “), and their causes and subclassifications are described. A paradigm for diagnosing ADRs is suggested and criteria are presented that assess the causal relationship between drug administration and clinical observations. Laboratory and clinical diagnostic and investigative methods that aid in ADR reporting mechanisms are reviewed. Methods to prevent ADRs and increase compliance in reporting are also discussed.
引用
收藏
页码：323 / 338
页数：15
相关论文
共 149 条
[1]  
Helper CD(1990)Opportunities and responsibilities in pharmaceutical care Am J Hosp Pharm. 47 533-543
[2]  
Strand LM(1995)Incidence of adverse drug events and potential adverse drug events. Implications for prevention JAMA. 274 29-34
[3]  
Bates DW(1996)Adverse drug reactions: establishing a hierarchy of definitions for adjustment of report rates Hosp Pharm. 31 1593-1595
[4]  
Cullen DJ(1976)Adverse drug reaction—a matter of opinion Clin Pharmacol Ther. 19 489-492
[5]  
Laird N(1970)Comprehensive drug surveillance JAMA. 213 1455-1460
[6]  
Trick OL(1973)Drug surveillance utilizing epidemiologic methods. A report from the Boston Collaborative Drug Surveillance Program Am J Hosp Pharm. 30 584-592
[7]  
Karch F(1997)Adverse drug events in hospitalized patients. Excess of length of stay, extra cost and attributable mortality JAMA. 277 301-306
[8]  
Smith C(1995)System analysis of adverse drug reaction JAMA. 274 35-43
[9]  
Kerzner B(1996)Drug-related illness in emergency department patients Am J Health Syst Pharm. 53 1422-1426
[10]  
Mazullo J(1992)Drug related emergency department visits and hospital admissions Am J Hosp Pharm. 49 1696-1700
12345678910